Jonathan P. Orme

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models

Stephen T. Durant, Li Zheng, Yingchun Wang et al. · Science Advances · 2018 · 312 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs

Jeffrey W. Johannes, Amber Balazs, Derek Barratt et al. · Journal of Medicinal Chemistry · 2021 · 140 citations · Full text

Life Sciences, Medicinal Chemistry, Oncology +13

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

Nicolas Floc’h, Matthew J. Martin, Jonathan W. Riess et al. · Molecular Cancer Therapeutics · 2018 · 111 citations · Full text

Medicine, Oncology, Pharmacology +16

Positioning High-Throughput CETSA in Early Drug Discovery through Screening against B-Raf and PARP1

Joseph Shaw, Ian L. Dale, Paul Hemsley et al. · SLAS DISCOVERY · 2018 · 49 citations · Full text

Pharmacy, Biochemistry, Molecular Biology +15

Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I

Nicolas Floc’h, Sangbin Lim, Sue Bickerton et al. · Molecular Cancer Therapeutics · 2020 · 49 citations · Full text

Medicine, Oncology, Pharmacology +17